HC Wainwright Issues Negative Estimate for CorMedix Earnings

CorMedix Inc (NASDAQ:CRMD) – Stock analysts at HC Wainwright dropped their Q1 2026 earnings per share estimates for shares of CorMedix in a research report issued to clients and investors on Thursday, March 5th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.38 per share for the quarter, down from their prior estimate of $0.73. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at $0.43 EPS, FY2027 earnings at $0.01 EPS, FY2028 earnings at $0.38 EPS, FY2029 earnings at $1.08 EPS and FY2030 earnings at $1.55 EPS.

Several other brokerages have also recently issued reports on CRMD. Weiss Ratings restated a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, January 21st. Zacks Research lowered CorMedix from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 10th. Needham & Company LLC reduced their price objective on CorMedix from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday. Royal Bank Of Canada set a $13.00 price objective on CorMedix and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Finally, Truist Financial set a $16.00 price objective on CorMedix in a research note on Thursday, January 8th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, CorMedix has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

CorMedix Price Performance

CRMD stock opened at $6.46 on Monday. CorMedix has a 52 week low of $5.60 and a 52 week high of $17.43. The firm has a market capitalization of $510.66 million, a P/E ratio of 3.23 and a beta of 1.31. The company has a fifty day simple moving average of $8.05 and a two-hundred day simple moving average of $10.31. The company has a quick ratio of 1.94, a current ratio of 2.11 and a debt-to-equity ratio of 0.36.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.70). The business had revenue of $128.62 million during the quarter, compared to the consensus estimate of $127.02 million. CorMedix had a return on equity of 52.30% and a net margin of 52.31%.The company’s revenue for the quarter was up 312.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.22 EPS.

CorMedix declared that its board has approved a stock buyback program on Monday, February 2nd that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 12.3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at CorMedix

In related news, Director Steven W. Lefkowitz sold 40,000 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $11.88, for a total value of $475,200.00. Following the sale, the director directly owned 80,498 shares of the company’s stock, valued at $956,316.24. This represents a 33.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Alan W. Dunton sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $13.00, for a total transaction of $260,000.00. Following the completion of the sale, the director directly owned 40,250 shares of the company’s stock, valued at approximately $523,250. The trade was a 33.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 90,000 shares of company stock worth $1,095,200. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On CorMedix

A number of institutional investors and hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. boosted its holdings in CorMedix by 17.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company’s stock valued at $81,000 after acquiring an additional 998 shares during the period. Russell Investments Group Ltd. lifted its position in shares of CorMedix by 22.2% during the second quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock worth $81,000 after purchasing an additional 1,190 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of CorMedix by 11.9% during the second quarter. China Universal Asset Management Co. Ltd. now owns 13,622 shares of the company’s stock valued at $168,000 after purchasing an additional 1,451 shares during the period. Palisades Investment Partners LLC boosted its stake in shares of CorMedix by 0.3% during the third quarter. Palisades Investment Partners LLC now owns 564,106 shares of the company’s stock valued at $6,561,000 after purchasing an additional 1,579 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of CorMedix by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,987 shares of the company’s stock worth $222,000 after purchasing an additional 1,631 shares during the last quarter. 34.18% of the stock is owned by institutional investors.

Key CorMedix News

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Q4 and full‑year results showed very strong top‑line growth and profitability (Q4 net revenue $128.6M; pro forma FY‑2025 net revenue $401.3M; adjusted EBITDA $77.2M; net income $14.0M), which supports valuation if growth persists. Earnings Release
• Positive Sentiment: Company discussion of a share buyback program and evolving REZZAYO data may reduce float and improve the risk/return profile, which investors view positively. Buyback & REZZAYO Article
• Neutral Sentiment: Multiple transcripts and conference‑call coverage are available for investors who want details from management on results, guidance and commercial progress. Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Short‑interest data in the feeds shows zeros/NaN values and a 0.0 days‑to‑cover metric—this appears to be a reporting glitch and is not a reliable signal. (No actionable short‑interest change confirmed.)
• Negative Sentiment: Reported EPS missed consensus by a wide margin, which triggered sell‑side and media coverage noting the stock decline after earnings; that EPS miss is the primary near‑term negative driver. Stock Drops After Earnings (Invezz)
• Negative Sentiment: FY‑2026 revenue guidance was provided at $300M–$320M, which sits around or slightly below some Street estimates (~$309.5M) and may temper near‑term upside if investors expected a more aggressive outlook. Press Release / Guidance
• Negative Sentiment: Needham cut its price target from $15 to $14 (but kept a Buy rating), a modest negative signal that may limit near‑term analyst‑driven upside. Needham PT Note

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.